PD-L1 Testing and Results in Lung Cancer

Share on: 

Programmed Cell Death Ligand-1 Testing Among Patients with Metastatic Non-Small Cell Lung Cancer: A Multinational Medical Record Review Study
Parikh RC, Klein AB, Kurosky S, Trantham L, Zhang Y, Levine CA, Kaye JA

Return to RTI-HS ISPOR Baltimore webpage to see what else we presented

Rohan Parikh, PhD
Associate Director, Health Economics
RTI Health Solutions

Lung cancer is the most common cancer in the world with millions of new cases being diagnosed each year. Millions of people die from it each year as well. In the last few years, the availability of immunotherapy agents has increased the number of effective treatments available for patients with metastatic non small-cell lung cancer. These therapies are associated with improved survival, longer duration of response, and fewer adverse events as compared to cytotoxic chemotherapies.

The objective of this study was to describe PD-L1 testing and results among patients in the US, UK, Germany, Spain, and Canada through a retrospective review of medical records

Testing at initial cancer diagnosis occurred [Insert figure 1 from poster] in about one-third of patients reviewed, and more patients received testing in 2017 than in 2015 or 16.  Positive results ranged from 17% in Spain to 35% in Canada. This identification of tumor PD-L1 expression at initial diagnosis may identify patients who are more likely to benefit from anti-PD-1 and anti-PD-L1 therapies.  

This study presents a historical perspective of PD-L1 testing prior to the adoption of highly effective immunotherapy agents in routine clinical practice.  As the use of these therapies increase, an increase in testing for PD-L1 expression may be observed as well.

 

Related Services:
Staff Members: